MDGL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Ribo and Madrigal achieved their first major milestone in developing novel siRNA therapies for MASHJul 2, 2026
- Madrigal Pharmaceuticals added a clinical-stage siRNA asset targeting PNPLA3 to its MASH pipelineMay 5, 2026
- Madrigal expanded its MASH pipeline through an exclusive global licensing agreement covering six preclinical siRNA programsFeb 11, 2026
- Madrigal receives European Commission approval for Rezdiffra™ (resmetirom) for treatment of MASH with moderate to advanced liver fibrosisAug 20, 2025
- Madrigal Pharmaceuticals enters exclusive global license agreement for oral GLP-1 receptor agonist with CSPC Pharmaceutical Group LimitedJul 30, 2025